Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. The Care Oncology Clinic offers a supervised treatment regimen for people diagnosed with cancer of any type or stage. AVRT is a physician-led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Its program includes a comprehensive online health evaluation; bloodtests to measure markers of inflammation and metabolism; an initial physician consultation; regular physician follow-up appointments and interval screening. Its additional cancer diagnostics include ColonSentry and the Prostate Health Index.


TSX:SZLS - Post by User

Comment by Bucky86on Sep 24, 2020 11:24am
145 Views
Post# 31611371

RE:Just like that

RE:Just like thatThere are two answers to question. If you want to do the current market value of this stock based on what is concrete what is in the books from the past and actually tangible then the answer is below $0.50 in my opinion. If you want to factor in speculation and quarter 3 assumptions or projections then maybe $1.50 ranging plus or minus $0.50 from there. Not going to get into the explanations of it but basically if you look at other stocks that are consistently over a dollar to $2 on our current Stock Exchange they consistently put up revenues in the millions annually. Unrelated example but even weed stocks that have 2 to 5 million in Revenue a year mind you with high overhead are in the $1 range plus or minus. Therefore our third quarter will be good and will show a high reflected stock price as will the Aristotle launch. But then the stock price will Retreat again until they're making consistent Revenue with Aristotle or covid-19. This is not a straight shot rocket ship to $5 in the NASDAQ by any means
<< Previous
Bullboard Posts
Next >>